Compare CTVA & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTVA | RMD |
|---|---|---|
| Founded | 2018 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.7B | 36.4B |
| IPO Year | N/A | 1995 |
| Metric | CTVA | RMD |
|---|---|---|
| Price | $72.87 | $258.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 12 |
| Target Price | $78.38 | ★ $291.10 |
| AVG Volume (30 Days) | ★ 3.5M | 846.0K |
| Earning Date | 02-03-2026 | 01-29-2026 |
| Dividend Yield | ★ 0.99% | 0.94% |
| EPS Growth | ★ 139.00 | 29.59 |
| EPS | 2.35 | ★ 9.77 |
| Revenue | ★ $17,469,000,000.00 | $5,257,400,000.00 |
| Revenue This Year | $6.91 | $9.88 |
| Revenue Next Year | $3.56 | $7.37 |
| P/E Ratio | $31.09 | ★ $26.15 |
| Revenue Growth | 5.00 | ★ 9.36 |
| 52 Week Low | $53.40 | $199.92 |
| 52 Week High | $77.41 | $293.81 |
| Indicator | CTVA | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 69.09 | 57.05 |
| Support Level | $68.42 | $250.19 |
| Resistance Level | $72.30 | $264.09 |
| Average True Range (ATR) | 1.34 | 5.98 |
| MACD | 0.28 | 0.27 |
| Stochastic Oscillator | 90.96 | 65.52 |
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva plans to spin off its seeds business in 2026 and will become a pure-play crop protection company following the divestiture. Corteva operates globally, but around half of revenue comes from North America.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.